Abstract
Aim: To evaluate the rates of endocrine abnormalities in survivors of childhood brain tumors and identify risk factors. Methods: The medical charts of patients were reviewed for background, disease-related and treatment-related data. Endocrine dysfunction was determined by clinical and laboratory evaluation. Results: The study group included 114 patients with a mean age of 15.57 ± 5.93 years. Mean age at brain tumor diagnosis was 7.07 ± 5.42 years, and mean follow-up was 12.8 ± 6.25 years. Fifty-seven patients (50%) had an endocrine abnormality. The occurrence of several endocrine abnormalities was significantly associated with cranial irradiation and age <16 years at tumor diagnosis. The presence of growth hormone deficiency (n = 40) was associated with cranial or spinal irradiation, younger age and prepubertal stage at tumor diagnosis; the presence of hypogonadotropic hypogonadism (n = 9) was associated with prepubertal stage at diagnosis, and hypothyroidism (n = 23) was associated with cranial irradiation. Hypocortisolism was diagnosed in 9 patients, short stature in 20 patients and obesity in 8 male patients. Patients with early puberty (n = 19) and an abnormal lipid profile (n = 15) were significantly younger at tumor diagnosis than patients without these disorders. Conclusions: Childhood brain tumor survivors are at increased risk of late endocrine effects, particularly those treated with cranial radiation and diagnosed at a younger age. The frequency of hormonal deficits increases with time, warranting lifelong surveillance.
References
1.
Packer RJ, MacDonald T, Vezina G: Central nervous system tumors. Pediatr Clin North Am 2008;55:121–145.
2.
Horner MJ, Ries LAG, Krapcho M, et al (eds): SEER Cancer Statistics Review 1975–2006. Bethesda, National Cancer Institute, 2009. http://seer.cancer.gov/csr/1975_2006/ (based on November 2008 SEER data submission, posted to the SEER website 2009).
3.
Robison LL, Green DM, Hudson M, Meadows AT, Mertrns AC, Packer RJ, Sklar CA, Strong LC, Yasui Y, Zeltzer LK: Long term outcomes of adult survivors of childhood cancer – results from the Childhood Cancer Study. Cancer 2005;104(11 suppl):2557–2564.
4.
Bleyer WA: Epidemiologic impact of children with brain tumors. Child Nerv Syst 1999;15:758–763.
5.
Anderson DM, Rennie KM, Ziegler RS, Neglia JP, Robison LR, Gurney JG: Medical and neurocognitive late effects among survivors of childhood central nervous system tumors. Cancer 2001;92:2709–2719.
6.
Gurney JG, Kadan-Lottick NS, Packer RJ, Neglia JP, Sklar CA, Punyko JA, Stovall M, Yasui Y, Nicholson HS, Wolden S, et al: Endocrine and cardiovascular late effects among adult survivors of childhood brain tumors: Childhood Cancer Survivor Study. Cancer 2003;97:663–673.
7.
Kuczmarski RJ, Ogden CL, Grummer-Strawn LM, et al: CDC growth charts: United States. Advance Data from Vital and Health Statistics, No 314. Hyattsville, National Center for Health Statistics, 2000.
8.
Rosenfield R: Puberty in the female and its disorders; in Sperling MA (ed): Pediatric Endocrinology, ed 2. Philadelphia, Elsevier Science, 2002, p 494.
9.
Styne DM: The testes: disorders of sexual differentiation and puberty in the male; in Sperling MA (ed): Pediatric Endocrinology, ed 2. Philadelphia, Elsevier Science, 2002, p 599.
10.
Dixon WJ: BMDP Statistical Software. Los Angeles, University of California Press, 1993.
11.
Peretz NM, Goldberg H, Kuten A, Meller I, Krivoi E, Lorber A, Bentur L, Lightman A, Gorenberg V, Ben Arush-Weyl M: Long-term sequelae of malignant tumors in childhood: consequences of late side effects (in Hebrew). Harefuah 2001;140:95–100.
12.
Darzy KH, Shalet SM: Hypopituitarism following radiotherapy revisited. Endocr Dev 2009;15:1–24.
13.
Spoudeas HA, Hindmarsh PC, Matthews DR, Brook CG: Evolution of growth hormone neurosecretory disturbance after cranial irradiation for childhood brain tumors: a prospective study. J Endocrinol 1996;150:329–342.
14.
Bercu BB, Diamond FB Jr: Growth hormone neurosecretory dysfunction. J Clin Endocrinol Metab 1986;15:537–590.
15.
Rappaport R, Brauner R, Czernichow P, Thibaud E, Renier D, Zucker JM, Lemerle J: Effect of hypothalamic and pituitary irradiation on pubertal development in children with cranial tumors. J Clin Endocrinol Metab 1982;54:1164–1168.
16.
Constine LS, Woolf PD, Cann D, Mick G, McCormick K, Raubertas RF, Rubin P: Hypothalamic-pituitary dysfunction after radiation for brain tumors. N Engl J Med 1993;328:87–94.
17.
Schmiegelow M, Lassen S, Poulsen HS, Schmiegelow K, Hertz H, Andersson AM, Skakkebaek NE, Muller J: Gonadal status in male survivors following childhood brain tumors. J Clin Endocrinol Metab 2001;86:2446–2452.
18.
Schmiegelow M, Feldt-Rasmussen U, Rasmussen AK, Lange M, Poulsen HS, Muller J: Assessment of the hypothalamo-pituitary-adrenal axis in patients treated with radiotherapy and chemotherapy for childhood brain tumor. J Clin Endocrinol Metab 2003;88:3149–3154.
19.
Spoudeas HA, Charmandari E, Brook CG: Hypothalamo-pituitary-adrenal axis integrity after cranial irradiation for childhood posterior fossa tumours. Med Pediatr Oncol 2003;40:224–229.
20.
Schmiegelow M, Feldt-Rasmussen U, Rasmussen AK, Poulsen HS, Muller J: Diagnosis of hidden central hypothyroidism in survivors of childhood cancer. J Clin Endocrinol Metab 1999;84:4472–4479.
21.
Rose SR, Lustig RH, Pitukcheewanont P, Broome DC, Burghen GA, Li H, Hudson MM, Kun LE, Heideman RL: Abnormalities of the thyroid in survivors of Hodgkin’s disease: data from the Childhood Cancer Survivor Study. J Clin Endocrinol Metab 2000;85:3227–3232.
22.
Sklar C, Whitton J, Mertens A, Stovall M, Green D, Marina N, Greffe B, Wolden S, Robison LL: A population-based study of thyroid function after radiotherapy and chemotherapy for a childhood brain tumor. J Clin Endocrinol Metab 2003;88:136–140.
23.
Ogilvy-Stuart AL, Shalet SM, Gattamaneni HR: Thyroid function after treatment of brain tumors in children. J Pediatr 1991;119:733–737.
24.
Tucker MA, Jones PH, Boice JD Jr, Robison LL, Stone BJ, Stovall M, Jenkin RD, Lubin JH, Baum ES, Siegel SE, et al: Therapeutic radiation at a young age is linked to secondary thyroid cancer. The Late Effects Study Group. Cancer Res 1991;51:2885–2888.
25.
Schneider AB, Ron E, Lubin J, Stovall M, Gierlowski TC: Dose-response relationships for radiation-induced thyroid cancer and thyroid nodules: evidence for the prolonged effects of radiation on the thyroid. J Clin Endocrinol Metab 1993;77:362–369.
26.
Lustig RH, Post SR, Srivannaboon K, Rose SR, Danish RK, Burghen GA, Xiong X, Wu S, Merchant TE: Risk factors for the development of obesity in children surviving brain tumors. J Clin Endocrinol Metab 2003;88:611–616.
27.
Schwartz MW, Woods SC, Porte D Jr, Seeley RJ, Baskin DG: Central nervous system control of food intake. Nature 2000;404:661–671.
28.
Israel Juvenile Diabetes Registry: The Israel Center for Disease Control, annual report 2010.
29.
Clayton PE, Shalet SM: Dose dependency of time of onset of radiation-induced growth hormone deficiency. J Pediatr 1991;118:226–228.
30.
Costin G: Effects of low-dose cranial radiation on growth hormone secretory dynamics and hypothalamic-pituitary function. Am J Dis Child 1988;142:847–852.
31.
Samaan NA, Vieto R, Schultz PN, Maor M, Meoz RT, Sampiere VA, Cangir A, Ried HL, Jesse RH Jr: Hypothalamic, pituitary and thyroid dysfunction after radiotherapy to the head and neck. Int J Radiat Oncol Biol Phys 1982;8:1857–1867.
32.
Livesey EA, Hindmarsh PC, Brook CG, Whitton AC, Bloom HJ, Tobias JS, Godlee JN, Britton J: Endocrine disorders following treatment of childhood brain tumors. Br J Cancer 1990;61:622–625.
33.
Schmiegelow M, Lassen S, Poulsen HS, Feldt-Rasmussen U, Schmiegelow K, Hertz H, Muller J: Cranial radiotherapy of childhood brain tumours: growth hormone deficiency and its relation to the biological effective dose of irradiation in a large population based study. Clin Endocrinol 2000;53:191–197.
34.
Clayton PE, Shalet SM: The evolution of spinal growth after irradiation. Clin Oncol 1991;3:220–222.
35.
Xu W, Janss A, Moshang T: Adult height and adult sitting height in childhood medulloblastoma survivors. J Clin Endocrinol Metab 2003;88:4677–4681.
36.
Shalet SM, Gibson B, Swindell R, Pearson D: Effect of spinal irradiation on growth. Arch Dis Child 1987;62:461–464.
37.
Achermann JC, Hindmarsh PC, Brook CG: The relationship between the growth hormone and insulin-like growth factor axis in long-term survivors of childhood brain tumours. Clin Endocrinol 1998;49:639–645.
38.
Olshan JS, Gubernick J, Packer RJ, D’Angio GJ, Goldwein JW, Willi SM, Moshang T Jr: The effects of adjuvant chemotherapy on growth in children with medulloblastoma. Cancer 1992;70:2013–2017.
39.
Nivot S, Benelli C, Clot JP, Saucet C, Adan L, Souberbielle JC, Zucker JM, Rappaport R, Brauner R: Nonparallel changes of growth hormone (GH) and insulin-like growth factor-I, insulin-like growth factor binding protein-3, and GH-binding protein, after craniospinal irradiation and chemotherapy. JClin Endocrinol Metab 1994;78:597–601.
40.
Shalet SM, Beardwell CG, Pearson D, Jones PH: The effect of varying doses of cerebral irradiation on growth hormone production in childhood. Clin Endocrinol 1976;5:287–290.
41.
Ogilvy-Stuart AL, Clayton PE, Shalet SM: Cranial irradiation and early puberty. J Clin Endocrinol Metab 1994;78:1282–1286.
© 2011 S. Karger AG, Basel
2011
Copyright / Drug Dosage / Disclaimer
Copyright: All rights reserved. No part of this publication may be translated into other languages, reproduced or utilized in any form or by any means, electronic or mechanical, including photocopying, recording, microcopying, or by any information storage and retrieval system, without permission in writing from the publisher.
Drug Dosage: The authors and the publisher have exerted every effort to ensure that drug selection and dosage set forth in this text are in accord with current recommendations and practice at the time of publication. However, in view of ongoing research, changes in government regulations, and the constant flow of information relating to drug therapy and drug reactions, the reader is urged to check the package insert for each drug for any changes in indications and dosage and for added warnings and precautions. This is particularly important when the recommended agent is a new and/or infrequently employed drug.
Disclaimer: The statements, opinions and data contained in this publication are solely those of the individual authors and contributors and not of the publishers and the editor(s). The appearance of advertisements or/and product references in the publication is not a warranty, endorsement, or approval of the products or services advertised or of their effectiveness, quality or safety. The publisher and the editor(s) disclaim responsibility for any injury to persons or property resulting from any ideas, methods, instructions or products referred to in the content or advertisements.
You do not currently have access to this content.
